Briacell Therapeutics
BCTX
19 hedge funds and large institutions have $17.9M invested in Briacell Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
12% more funds holding
Funds holding: 17 → 19 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.11% → 0.12% (+0%)
8% less capital invested
Capital invested by funds: $19.4M → $17.9M (-$1.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
+$594K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$419K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$354K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$253K |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$469K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$77.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$77K |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$25.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.8K |
BCTX Hedge Fund Activity: Q2 2023 in Review
19 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2023, worth a combined $17.9M — down 7.8% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BCTX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Natixis, opening a new position worth an estimated $594K. The largest seller was K.J. Harrison & Partners, cutting an estimated $469K.
- 19 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2023, up from 17 in Q1 2023.
- Funds reported $17.9M of Briacell Therapeutics stock for Q2 2023, down 7.8% quarter-over-quarter.
- 5 funds opened new Briacell Therapeutics positions in Q2 2023 and 3 closed out, a net change of +2 holders.
- The largest Briacell Therapeutics buyer in Q2 2023 was Natixis, an estimated $594K added.
- The largest Briacell Therapeutics seller in Q2 2023 was K.J. Harrison & Partners, an estimated $469K sold.
Based on aggregated 13F filings for Q2 2023.